1
Indications & Contraindications
Patient selection, when to pursue TDE
Indications
- Chylothorax refractory to conservative management — >2 weeks of persistent output or >1 L/day high-output leak
- Post-surgical chyle leak — esophagectomy, spine surgery, neck dissection
- Traumatic thoracic duct injury — penetrating or blunt mechanism with documented chyle leak
- Chylous ascites refractory to conservative treatment (dietary modification, octreotide, paracentesis)
- Pleural fluid triglycerides ≥110 mg/dL with chylomicrons present confirms chylous etiology
Contraindications
- No identifiable cisterna chyli — cannot be opacified on lymphangiography; no target for access
- Patient too unstable for prolonged procedure under moderate sedation
- Inability to access cisterna chyli — interposed structures (aortic aneurysm, bowel) blocking percutaneous path
- Uncorrectable coagulopathy
- Relative: severe pulmonary disease or right-to-left cardiac shunt (risk of Lipiodol embolization)
When to Proceed with TDE vs. Conservative Management
| Feature | Conservative Management | TDE Indicated |
|---|---|---|
| Output volume | <500 mL/day | >1 L/day or persistent >500 mL/day after 2 weeks |
| Duration | <2 weeks | >2 weeks without improvement |
| Diet modification | Responding to MCT diet / NPO + TPN | Failed conservative dietary management |
| Etiology | Low-flow, non-surgical | Post-surgical or traumatic with identifiable duct injury |
| Surgical option | Not yet considered | TDE preferred as less invasive alternative to thoracoscopic ligation |
2
Pre-Procedure Planning
Lymphangiography first, labs, patient prep, consent
Lymphangiography (REQUIRED First)
- Intranodal or pedal lymphangiography MUST be performed before TDE — opacifies the cisterna chyli, maps thoracic duct anatomy, and localizes leak site
- Lipiodol (iodinated oil contrast) used; stays within lymphatic system unlike water-based agents
- Lipiodol dose limited to ~20 mL per procedure to minimize pulmonary oil embolization risk
- Lipiodol itself is therapeutic in ~50% of chyle leaks (may seal leak without need for TDE)
- MR lymphangiography if available — provides pre-procedural roadmap of lymphatic anatomy
Labs & Patient Preparation
- Labs: CBC, PT/INR (≤1.5), platelets (≥50K), BMP
- NPO or medium-chain triglycerides (MCT) diet to reduce chyle flow before procedure
- Review cross-sectional imaging: identify retroperitoneal anatomy, cisterna chyli location, aortic position
- Chest tube in place for chylothorax drainage — output monitoring pre- and post-procedure
- IV access established; moderate sedation planned
Lymphangiography completed. Cisterna chyli opacified with Lipiodol; thoracic duct anatomy and leak site identified on fluoroscopy.
Coagulopathy corrected. INR ≤1.5, platelets ≥50K before proceeding.
Cross-sectional imaging reviewed. Retroperitoneal anatomy assessed; no interposed aortic aneurysm or bowel in planned access path.
Consent obtained. Key risks discussed: ~70% technical success rate, ~30% failure rate (cisterna access is the limiting step), chylous ascites, fat embolism, bleeding, infection.
NPO / MCT diet initiated to reduce chyle flow and improve visualization.
Chest tube output documented as baseline for post-procedure comparison.
3
Relevant Anatomy
Cisterna chyli, thoracic duct course, key landmarks
Cisterna Chyli
- Located at L1–L2 level, anterior to the vertebral body, posterior to the aorta, typically right of midline
- Confluence of lumbar lymphatic trunks and intestinal trunk
- Serves as the origin of the thoracic duct
- Opacified by Lipiodol during lymphangiography — this is the primary target for percutaneous access
- Variable anatomy: may be a single sac, plexiform network, or absent in ~20% of patients
Thoracic Duct Course
- Arises from cisterna chyli and courses superiorly through the posterior mediastinum
- Travels between the aorta and azygos vein, anterior to the vertebral bodies
- Crosses to the LEFT side at T5–T6 — key anatomic landmark
- Empties into the left subclavian / internal jugular venous junction (left venous angle)
- Total length ~38–45 cm; 2–3 mm diameter; single duct in ~50%, duplicated or plexiform in remainder
Clinical Significance for TDE
The thoracic duct is most commonly injured during esophagectomy, spine surgery, or neck dissection because of its intimate relationship with the esophagus and vertebral bodies. Injuries below T5–T6 typically cause right-sided chylothorax (duct is right-sided in the lower mediastinum), while injuries above T5–T6 cause left-sided chylothorax (duct has crossed to the left). The cisterna chyli is the access point for TDE because it is the largest, most accessible portion of the lymphatic system when opacified with Lipiodol.
4
Supplies & Setup
Access needles, embolization materials, catheters
Access & Catheters
- 22G Chiba needle (15–20 cm) for cisterna chyli puncture
- Non-vascular access kit with 21G trocar needle
- 0.018-in. microwire
- 2.5–3.0 Fr inner catheter (triaxial system)
- 3 Fr microcatheter (80 cm, e.g. SlipCath) for thoracic duct catheterization
- 0.025-in. Bentson wire (coil pusher)
Embolization Materials
- Microcoils (0.018-in. compatible) — multiple sizes for thoracic duct occlusion
- n-Butyl cyanoacrylate (NBCA) glue (TRUFILL) — 1:1 to 1:2 ratio glue:Lipiodol
- Tantalum powder for glue radiopacity
- Polycarbonate syringes (3 mL) for glue mixing
- Sterile shot glass for glue preparation
- Lipiodol (Guerbet) — for lymphangiography and glue dilution
General Supplies & Medications
- Standard procedural tray: sterile drapes, 25G/22G needles, lidocaine 1%
- Cefazolin 1 g IV (pre-procedure antibiotic)
- Moderate sedation: midazolam + fentanyl
- Fluoroscopy suite with high-quality imaging
- CT guidance available (backup for difficult cisterna access)
- Heavy cream via NG tube (optional — enhances chyle flow for visualization)
5
Procedure Steps
Lymphangiography, cisterna access, duct catheterization, embolization
1
Lymphangiography to Opacify Cisterna Chyli
Perform intranodal or pedal lymphangiography with Lipiodol to opacify the cisterna chyli and thoracic duct. Confirm cisterna chyli visualization on fluoroscopy. Identify the thoracic duct course and leak location. If cisterna chyli not visible, consider re-injection with additional Lipiodol or administering heavy cream via NG tube to enhance chyle flow.
2
Positioning & Transabdominal Access
Position patient supine. Sterile prep over the abdomen/flank. Under fluoroscopic guidance, advance a 22G Chiba needle transabdominally to target the Lipiodol-opacified cisterna chyli at L1–L2 level. The cisterna chyli appears as a radiopaque structure anterior to the vertebral body, posterior to the aorta. Local anesthesia with lidocaine 1% along the needle tract.
3
Cisterna Chyli Puncture & Wire Access
Puncture the cisterna chyli with the 22G Chiba needle under fluoroscopic guidance. Confirm intralymphatic position by aspirating chylous fluid or injecting small amount of contrast to confirm opacification within the lymphatic system. Advance a 0.018-in. microwire into the cisterna chyli through the access needle.
4
Catheterize the Thoracic Duct
Exchange access needle over the wire for a 2.5–3.0 Fr catheter. Advance the microcatheter (3 Fr) over the wire into the thoracic duct. Navigate superiorly through the duct under fluoroscopic guidance. Perform contrast injection through the catheter to map the duct and confirm the leak site.
5
Embolize the Thoracic Duct
If catheter can be advanced past the leak site: Deploy microcoils across the leak site to occlude the thoracic duct. Follow with NBCA glue injection (1:1 to 1:2 glue:Lipiodol ratio) for complete occlusion. Combined coil + glue embolization is most effective. — If catheter cannot traverse the leak: Embolize the thoracic duct proximal to the leak with coils/glue. Then perform cisterna chyli disruption by needle disruption + glue injection to redirect lymphatic drainage via collateral pathways.
6
Post-Embolization Assessment & Needle Removal
Perform final fluoroscopic assessment to confirm thoracic duct occlusion and glue/coil positioning. Verify no contrast extravasation at the prior leak site. Remove catheter and access needle. Apply pressure at the skin entry site. Monitor chest tube output immediately post-procedure for reduction in chyle drainage.
Community Cards
Sign in to view and create community cards
6
Troubleshooting
Intraoperative problems and solutions
Cisterna Not Visible
Cannot Visualize Cisterna Chyli on Fluoroscopy
Re-perform lymphangiography with additional Lipiodol (up to 20 mL total dose limit). Consider administering heavy cream via NG tube to enhance chyle flow and improve opacification. Allow additional time (30–60 min) for Lipiodol to transit through the lymphatic system. If still not visible, consider MR lymphangiography or CT-guided approach.
Access Failure
Cannot Access the Cisterna Chyli Percutaneously
Try different needle angles and entry points. Consider switching to CT guidance for improved cross-sectional visualization if working under fluoroscopy alone. Use a longer needle (20 cm) if patient body habitus requires it. If the cisterna is absent or too small to access, TDE cannot be performed — refer for thoracoscopic duct ligation.
Cannot Traverse Leak
Catheter Cannot Be Advanced Past the Leak Site in the Thoracic Duct
Attempt different wire and catheter combinations to navigate past the disruption. If unable to traverse: embolize the thoracic duct proximal to the leak site with coils and/or NBCA glue. Perform cisterna chyli disruption using the access needle (needle disruption technique) followed by glue injection to seal the cisterna and promote collateral lymphatic drainage.
Glue Reflux
NBCA Glue Refluxing into Catheter or Non-Target Lymphatics
Inject glue slowly under continuous fluoroscopic monitoring. Stop injection immediately if glue refluxes into the catheter. Adjust glue:Lipiodol ratio (more Lipiodol = slower polymerization, more control). Ensure coils are placed first to provide a scaffold that limits glue migration. Don new sterile gloves before handling glue to avoid premature polymerization from ionic contamination.
7
Complications
Procedural risks and management
Common / Expected
- Procedure failure (~30%) — inability to access cisterna chyli is the most common cause of technical failure; refer for thoracoscopic ligation
- Transient abdominal/back pain — from needle puncture and cisterna manipulation; self-limited
- Minor bleeding at access site — controlled with manual pressure
Serious Complications
- Chylous ascites — if cisterna chyli is disrupted without adequate sealing; may require paracentesis; usually self-limited as collateral pathways develop
- Fat embolism — from Lipiodol entering systemic venous circulation; monitor O2 saturation; keep Lipiodol dose ≤20 mL
- Pneumothorax — from needle traversing pleural space; post-procedure CXR; chest tube if symptomatic
- Bleeding / retroperitoneal hematoma — vascular injury during transabdominal access; usually self-limited with 22G needle
- Infection — rare with sterile technique; prophylactic cefazolin given
- Non-target embolization — glue migration; careful fluoroscopic monitoring during injection
8
Pearls & Pitfalls
Key tips for technical success
✦
Technical success ~70%. Cisterna chyli access is the rate-limiting step. If the cisterna cannot be identified or accessed, TDE cannot be performed.
✦
Lymphangiography MUST be done first. You cannot see the target without it. The cisterna chyli is invisible on fluoroscopy without Lipiodol opacification.
✦
Lipiodol itself is therapeutic in ~50% of leaks. Lymphangiography alone may seal the chyle leak without proceeding to TDE. Monitor chest tube output after lymphangiography before committing to TDE.
✦
Combined coil + glue embolization is most effective. Coils provide a scaffold; glue provides complete occlusion. Use both for highest success rate.
✦
High-output leaks (>1 L/day) = higher urgency. These patients are losing significant protein, electrolytes, and immunoglobulins daily. Nutritional depletion and immunosuppression escalate rapidly.
⚠
If TDE fails, thoracoscopic ligation is the surgical fallback. Communicate this possibility to the surgical team before attempting TDE so the patient is consented for both options.
⚠
Lipiodol dose limit: ~20 mL per procedure. Exceeding this increases pulmonary oil embolization risk, especially in patients with right-to-left shunts or severe pulmonary disease.
⚠
Don new sterile gloves before handling NBCA glue. Ionic contamination from prior glove contact will cause premature polymerization, rendering the glue unusable.
9
References & Resources
Primary sources and related procedures
Surgical Alternative
- Thoracoscopic thoracic duct ligation — surgical option when TDE fails (~30% of cases); direct visualization and clipping of the thoracic duct
- Pleurodesis — considered for recurrent chylothorax not amenable to duct intervention
Primary References
- Itkin M, Kucharczuk JC, Yoder BA, Patel N, Fisher CA, Kaiser LR. Nonoperative thoracic duct embolization for traumatic thoracic duct leak: experience in 109 patients. J Vasc Interv Radiol. 2010;21(5):642–650.
- Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. Radiology. 1999;213(2):489–495.
- Stecker MS, Fan CM. Lymphangiography for thoracic duct interventions. Tech Vasc Interventional Rad. 2016;19:277–285.
- Nadolski GJ, Itkin M. Feasibility of ultrasound-guided intranodal lymphangiogram for thoracic duct embolization. J Vasc Interv Radiol. 2012;23(5):613–616.